A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. (Q54656049)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. |
scientific article |
Statements
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. (English)
1 reference
Dale R Shepard
1 reference
Matthew M Cooney
1 reference
Paul Elson
1 reference
Ronald M Bukowski
1 reference
Robert Dreicer
1 reference
Brian I Rini
1 reference
Jorge A Garcia
1 reference
14 August 2010
1 reference
30
1 reference
1
1 reference
364-367
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference